PubRank
Search
About
Steen Dalby Kristensen
Author PubWeight™ 109.81
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
J Hypertens
2007
20.09
2
Universal definition of myocardial infarction.
Circulation
2007
11.69
3
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Eur Heart J
2013
9.54
4
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Eur Heart J
2007
9.43
5
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
Eur J Cardiovasc Prev Rehabil
2007
6.10
6
Concern
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery.
Eur Heart J
2009
3.14
7
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
Eur J Cardiovasc Prev Rehabil
2007
2.70
8
Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries.
Eur Heart J
2009
2.68
9
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
J Am Coll Cardiol
2012
2.41
10
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Lancet
2013
2.39
11
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.
Lancet
2010
2.38
12
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.
Thromb Haemost
2014
2.29
13
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).
Eur Heart J
2014
2.10
14
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA).
Eur J Anaesthesiol
2010
1.92
15
Anticoagulants in heart disease: current status and perspectives.
Eur Heart J
2007
1.73
16
Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety.
Thromb Res
2005
1.62
17
Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial).
Am J Cardiol
2012
1.59
18
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).
Eur J Anaesthesiol
2014
1.59
19
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation].
G Ital Cardiol (Rome)
2009
1.52
20
Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial.
Circulation
2006
1.49
21
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
Thromb Haemost
2013
1.36
22
A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease.
Thromb Haemost
2010
1.24
23
Antiplatelet agents for the treatment and prevention of atherothrombosis.
Eur Heart J
2011
1.23
24
Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).
Circulation
2012
1.17
25
Letter by Grove and Kristensen regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
Circ Cardiovasc Interv
2013
1.07
26
Long genuine coronary artery lesions treated with stiff tubular or flexible coiled stents. A randomized angiographic follow-up study.
Scand Cardiovasc J
2002
1.07
27
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
Thromb Haemost
2013
0.99
28
Determinants and patterns of utilization of primary percutaneous coronary intervention across 12 European countries: 2003-2008.
Int J Cardiol
2013
0.97
29
How to set up an effective national primary angioplasty network: lessons learned from five European countries.
EuroIntervention
2009
0.96
30
Time to treatment and three-year mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction-a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) substudy.
Am J Cardiol
2010
0.94
31
Immature platelets in patients with acute coronary syndromes.
Thromb Haemost
2009
0.94
32
[ESH/ESC 2007 Guidelines for the management of arterial hypertension].
Rev Esp Cardiol
2007
0.90
33
Platelet aggregation is dependent on platelet count in patients with coronary artery disease.
Thromb Res
2011
0.90
34
Pharmacogenetics of the antiplatelet effect of aspirin.
Curr Pharm Des
2012
0.84
35
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
Thromb Haemost
2016
0.83
36
Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study.
BMC Cardiovasc Disord
2014
0.83
37
Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.
PLoS One
2013
0.82
38
Rapid evaluation of platelet function using the Multiplate® Analyzer.
Platelets
2013
0.81
39
Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction.
Thromb Haemost
2012
0.81
40
3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents.
JACC Cardiovasc Interv
2012
0.81
41
Stent for Life Initiative: where are we standing and where are we going?
Eur Heart J Acute Cardiovasc Care
2012
0.79
42
Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines.
Expert Rev Cardiovasc Ther
2012
0.79
43
[Guidelines for cardiac pacing and cardiac resynchronization therapy].
Rev Port Cardiol
2008
0.78
44
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Platelets
2012
0.78
45
Monitoring aspirin therapy with the Platelet Function Analyzer-100.
Scand J Clin Lab Invest
2008
0.77
46
New anticoagulants for atrial fibrillation.
J Cardiovasc Med (Hagerstown)
2009
0.76
47
Outcome of unprotected left main percutaneous coronary intervention in surgical low-risk, surgical high-risk, and acute myocardial infarction patients.
EuroIntervention
2006
0.76
48
Do the Behring Coagulation Timer and the Platelet Function Analyzer-100 identify the same patients as being aspirin non-responders?
Platelets
2007
0.75
49
[Guidelines in cardiac pacing and resynchronization therapy].
Kardiol Pol
2007
0.75
50
[Clopidogrel: background information and use in clinical practice].
Ugeskr Laeger
2003
0.75
51
Aspirin resistance: myth or major problem?
Scand J Clin Lab Invest
2008
0.75
52
Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events.
Thromb Haemost
2016
0.75
53
Pain and discomfort in closure of femoral access coronary angiography. The CLOSuredEvices Used in everyday Practice (CLOSE-UP) pain sub study.
Eur J Cardiovasc Nurs
2013
0.75
54
Establishing primary angioplasty as the preferred treatment for acute myocardial infarction.
Scand Cardiovasc J
2002
0.75
55
[Bleeding complications after treatment with antithrombotic agents after acute coronary syndrome].
Ugeskr Laeger
2006
0.75
56
Scintigraphic evaluation of routine filterwire distal protection in percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: a randomized controlled trial.
J Nucl Cardiol
2009
0.75
57
CardioPulse Articles.
Eur Heart J
2014
0.75
58
Randomized comparison of deliverability and in-hospital complications in implantation of BxSonic(R), Express(R), and Flexmaster(R) coronary stents.
EuroIntervention
2005
0.75
59
The German Centre for Cardiovascular Research.
Eur Heart J
2012
0.75